Initial presentation on January 26, 2026 s howcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (Nasdaq:TIVC), a late-stage immuno-therapeutics company, today announced that a second, follow-up meeting with the Biomedical Advanced Research and Development Authority (BARDA) has been scheduled for March 10, 2026, to continue discussions focused on clinical data and the p ...

Core Insights - NeuroSense Therapeutics announced a statistically significant 65% reduction in the risk of death and a median survival benefit of over 14 months for patients with ALS treated with PrimeC [1] Group 1: Clinical Trial Results - The updated analysis from the PARADIGM Phase 2b clinical trial shows that patients receiving PrimeC had a median survival of 36.3 months compared to 21.4 months for those on placebo, indicating a 70% increase in median survival [1] - The survival benefit was consistent over time, with a log-rank test showing statistical significance (p = 0.0218) [1] - A Cox proportional hazards model indicated that PrimeC treatment was associated with a hazard ratio of 0.35, reflecting a 65% reduction in the risk of death compared to placebo (p = 0.0037) [1] Group 2: Company Overview - NeuroSense is a late-stage clinical biotechnology company focused on developing treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's [1] - The company aims to address significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options [1] - NeuroSense's strategy involves developing combined therapies targeting multiple pathways associated with these diseases [1] Group 3: Product Information - PrimeC is NeuroSense's lead drug candidate, a novel extended-release oral formulation combining ciprofloxacin and celecoxib, designed to target mechanisms contributing to neuron degeneration and inflammation [1] - The company continues to engage with regulatory authorities to advance PrimeC into pivotal late-stage development, reinforcing the clinical and regulatory foundation for the drug [1]

Achieved a record $1.4 billion in total revenue for 2025, a 38% increase driven by a 52% surge in royalty revenue from core blockbuster franchises. Transformed the corporate profile from two to four drug delivery technologies through the acquisitions of Elektrofi (Hypercon) and Surf Bio, extending IP protection into the mid-2040s. Performance was anchored by DARZALEX FASPRO, which now holds a 97% share of sales in the U.S., and PHESGO, which surpassed its initial 50% conversion target to reach 54%. ...

Swedish Orphan Biovitrum (OTCPK:SWOB.Y) 2026 Capital Markets Day February 18, 2026 07:00 AM ET Company ParticipantsDuane H. Barnes - Head of North AmericaEvangelos Giamarellos-Bourboulis - Chair of European Sepsis AllianceGerard Tobin - Head of Investor RelationsGuido Oelkers - CEOHenrik Stenqvist - CFOKirsty Ross-Stewart - VP of Pharmaceuticals Equity ResearchKlaus Parhofer - Professor of Metabolism and EndocrinologyLydia Abad-Franch - Head of R&D and Chief Medical OfficerMattias Häggblom - Co-Head of Equi ...

HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event:Oppenheime ...

Core Viewpoint - Vaxart, Inc. is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting its focus on developing oral vaccines using a proprietary delivery platform [1][2]. Company Overview - Vaxart is a clinical-stage biotechnology company specializing in oral recombinant vaccines that can be stored and shipped without refrigeration, thus eliminating needle-stick injury risks [3]. - The company is developing vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV), marking its entry into immune-oncology [3]. - Vaxart has filed extensive domestic and international patent applications for its oral vaccination technology, which utilizes adenovirus and TLR3 agonists [3]. Presentation Details - The presentation is scheduled for February 25, 2026, at 4:00 PM ET, and will be available for 30 days on the company's investor relations website [2]. - Vaxart will also engage in one-on-one meetings during the conference for interested investors [2].

WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), held February 18-21, 2026 in Stockholm, Sweden. “We are excited to share follow-up data out to 20 weeks fro ...

- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - Rasayana to assume all responsibility and costs for SYN-020 development and commercialization - ROCKVILLE, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas ...

Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational and strategic benefits for internal and future partnered assets WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gener ...

ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company anticipates reporting proof-of-concept data in the first quarter of 2027 ASCEND is the first of four clinical trials across the portfolio expected to initiate in 2026 WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-sta ...